Recon: PhRMA launches direct-to-consumer drug site; Shutdown would prompt HHS to furlough 41% of staff
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- US lobby group PhRMA plans website to boost access to cheaper drugs (Reuters) (Bloomberg)
- White House's 'most favored nation' deadline spurs flurry of pharma concessions (Endpoints)
- US government shutdown to furlough 41% of health agency workers (Reuters)
- Trump to Face Off With Democrats Ahead of Shutdown Deadline (Bloomberg)
- Kala Bio plunges after scrapping development of lead drug (Reuters)
- AstraZeneca to list shares in New York while keeping London listing (STAT)
- AbbVie to launch ovarian cancer drug in UK at US price (Reuters)
- Germany assumes 15% U.S. tariff rate will apply to pharma, heavy trucks (Reuters)
- Bavarian Nordic Bidders Extend Offer Deadline, Maintain Price (Bloomberg)
- Egypt Flexes Export Muscle With Surging Dietary Supplement Trade (Bloomberg)
- MedTech Europe pressures EU to make regulatory changes by early 2026 (MedTech Dive)
- Perimenopause is the new buzzword in the business of women’s health (STAT)
- As investor for AHA, ‘Venture Valkyrie’ argues ‘good medicine is good business’ (STAT)
- Genmab to buy Merus in $8B deal (STAT)
- Lilly executives: How the FDA’s new PreCheck program can unleash the future of U.S. medicine manufacturing (STAT)
- MoonLake can’t spin away this disastrous autoimmune drug failure (STAT)
- GSK CEO Walmsley to step down, be succeeded by company’s commercial lead (STAT)
- Enanta's RSV treatment misses main goal in mid-stage study (Reuters)
- Larimar's update on Friedreich's ataxia drug derailed by allergic reactions (Endpoints)
- Tourmaline attracted small bidding war before $1.4B sale to Novartis (Endpoints)
- IO Biotech to run another study for cancer vaccine; Boehringer ends mid-stage IPF trial (Endpoints)
- Exclusive: Once a mental health chatbot, Wysa acquires physical therapy startup Kins (Endpoints)
- Prosthetics Firm Ottobock, Owner Seek €702 Million in IPO (Bloomberg)
- SS Innovations hires new CFO (MedTech Dive)
- Biolinq gets FDA de novo nod for intradermal glucose sensor (MedTech Dive)
- J&J’s Abiomed Issues Third Recall Of Automated Impella Controllers Since June (MedTech Insight)
- A matcha shortage is coming for social media’s latest obsession (Food Dive)
- Recall impacts corn dogs, sausage-on-a-stick products (The Hill)
- Cannabis stocks surge after Trump endorses cannabidiol for senior healthcare (Reuters)
- Bedside Upgrade: Glooko Pushes Into Hospitals With Monarch EndoTool Deal, Targeting $1Bn Market (MedTech Insight)
- Section 232 probe reignites tariff uncertainty for medtech firms (MedTech Dive)
- OIG Urges Reforms To Medicare Skin Substitute Payments (MedTech Insight)
- Supply of Birth Control Pills in the US at Risk as Tariffs Kick In (Bloomberg)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
